Professor Suzhan Zhang, MD

Professor Suzhan Zhang, MD

Director, Cancer Institute
Zhejiang University Multidisciplinary Diagnosis and Treatment Center for Colorectal Cancer
Zhejiang University School of Medicine
Hangzhou, China

Related Videos

What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing? Video

What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing?

What sources are used, and should be used in China, to determine what targeted, anti-cancer therapies should be deployed in genomic alterations detected by NGS sequencing? “Broad molecular profiling” is already recommended for 1st line ...

What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE? Video

What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?

What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?

In what ways does NGS and CGP address the fundamental changes that cancer treatment is undergoing toward the use of molecularly targeted drugs prescribed to patients across tumor types? Video

In what ways does NGS and CGP address the fundamental changes that cancer treatment is undergoing toward the use of molecularly targeted drugs prescribed to patients across tumor types?

In what important ways does NGS and CGP address the fundamental changes that systemic cancer treatment is undergoing toward the use of molecularly targeted drugs prescribed to patients across multiple tumor types?

For which solid tumors do you find NGS genomic profiling to be most valuable for identifying molecular drivers that can reliably guide the use of targeted therapy? Video

For which solid tumors do you find NGS genomic profiling to be most valuable for identifying molecular drivers that can reliably guide the use of targeted therapy?

For which solid tumors do you find NGS genomic profiling to be most valuable for identifying molecular drivers that can reliably guide the use of targeted therapy?